Headlines about RXi Pharmaceuticals (NASDAQ:RXII) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. RXi Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.1419378961307 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
- Keep Your Active Eyes on RXi Pharmaceuticals Corporation (RXII) – Wall Street Morning (wallstreetmorning.com)
- RXi Pharmaceuticals to Present at Immuno-Oncology Frontiers World Conference (prnewswire.com)
- RXi Pharma Outlines 2018 Business Strategy (nasdaq.com)
- RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth (finance.yahoo.com)
Shares of RXi Pharmaceuticals (RXII) traded down $0.11 during mid-day trading on Friday, reaching $4.42. 17,265 shares of the company traded hands, compared to its average volume of 62,428. RXi Pharmaceuticals has a 52 week low of $3.20 and a 52 week high of $11.20. The stock has a market capitalization of $10.73, a PE ratio of -0.41 and a beta of 1.38.
ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3147772/rxi-pharmaceuticals-rxii-getting-somewhat-positive-media-coverage-analysis-finds.html.
RXi Pharmaceuticals Company Profile
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.